Monsanto merger with P&U nears
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MONSANTO, THE pharmaceuticals giant and Pharmacia & Upjohn, the Swedish drugmaker, are believed to be close to agreement on a mooted $55bn merger following a series of top level meetings in London over the weekend.
Discussions are said to be at an advanced stage and an announcement is expected this week, possibly as early as today. If the merger goes ahead, the two groups are likely to combine their pharmaceutical businesses and sell Monsanto's agriculture unit in a no-premium merger of equals.
An alliance between the two groups would create a company with revenues of $15.54bn (pounds 9.71bn) and a combined market capitalisation of about $53.21bn. If the deal goes ahead, Fred Hassan, P&U's chief executive, is expected to take up the post of CEO of the enlarged group. Robert Shapiro, Monsanto's chief, would become chairman.
The merger would be the latest round of consolidation in the rapidly restructuring pharmaceuticals sector. Novartis, the Swiss life science group and AstraZeneca, its Anglo-Swedish rival, recently agreed to merge their agrobusinesses. And US Pfizer and American Home Products are currently embroiled in a bitter takeover fight for Warner-Lambert.
Monsanto's GD Searle pharmaceuticals unit makes Celebrex, the arthritis drug, and Ambien, a sleeping aid. P&Usells Xalatan, a leading glaucoma drug, Detrol, the incontinence drug and Rogaine, the hair-growth product.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments